Company intelligence / Profile preview
Cytograft Tissue Engineering
Novato, California, USAcytograft.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cytograft demonstrated successful preclinical and early clinical results with its fully biological, tissue-engineered vascular grafts. The company’s “Lifeline” product showed promise as an alternative to synthetic grafts for hemodialysis access and bypass surgery, with advantages in biocompatibility and reduced infection risk. Allogeneic versions were successfully implanted in humans without immune rejection. However, the company is now inactive and did not reach full commercialization.
- Therapeutic areas
- NephrologyCardiovascular
- Modalities
- Cell therapyBiologicTissue-engineered grafts (including autologous and allogeneic constructs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with academic institutions for clinical research
Beyond the preview
Go deeper on Cytograft Tissue Engineering.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytograft Tissue Engineering.